Ubs Oconnor LLC Galmed Pharmaceuticals Ltd. Transaction History

Ubs Oconnor LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 13, 2019	SELL	$7.27 - $9.07 $325,405 - $405,973	-44,760 Reduced 42.11%	61,540 $0
Q4 2018 Feb 15, 2019	SELL	$6.59 - $14.47 $74,137 - $162,787	-11,250 Reduced 9.57%	106,300 $726,000
Q3 2018 Nov 14, 2018	SELL	$10.55 - $15.28 $78,597 - $113,836	-7,450 Reduced 5.96%	117,550 $0
Q2 2018 Aug 14, 2018	BUY	$5.04 - $17.96 $630,000 - $2.25 Million	125,000 New	125,000 $0

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $122M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.